Astra Zeneca CEO said in Conference call on Oct.25,2012-- 25 days in office.
1) Patents Cliff is taking toll on our numbers-Sales/profits already this year.Even Crestor Generic is hurting Canadian Sales.
2) Flexible/Open to Acquisitions. AZN could be looking at Amarin seriously as this is the best way to boost sales in 2013. Geoff Foster of DailyMail News article is real.
3) R&D productivity is his immediate focus.He is not going to compete on "Who spends most"?
4) Diabeties drug acquired from Amylin in Aug.2012--started hiring sales force in USA(It could be Bristol Myers),but not yet in Europe. Point to be noted-- Acquired in July,2012-- Not hired so far in Europe and even in USA it has taken 3 months. It is Control issue legally. Legally BMY or AZN gets control in 3 months after formal agreement.
This means even if AZN signs an agreement in next 30-60 days,they will NOT hire Sales force for 120-150 days-- 4 to 5 months. So Amarin will have to hire Sales force itself to launch in Jan.2013. Yes--they may hire less or those hired could merge with the ACQUIRER's Sales force as happens in any Merger.
If you read Amylin's filings with SEC in July,2012 after signing an agreement.
They stated in April 19,2012--
" The company Board determined that a private process of soliciting interest was preferable to public auction--because the launch of BYDUREON was in early stages and it was IMPORTANT that the Company's Sales remained focused on the launch and not be DISTRACTED by a Public process for selling the company". Source: SEC filings -July 10,2012 under Background of Offer.